Biotech companies hire full-time CMOs too early or too late. Too early burns runway on a role the company isn't ready to support. Too late means scrambling to build commercial infrastructure months before launch. A fractional CXO gives you senior leadership on a timeline that matches your pipeline.
The Problem
Your board wants a commercial strategy but you can't justify a full-time CMO
Boards now push for commercial readiness evidence at Series B, not just at pre-launch. But hiring a $400K CMO to build a plan you won't execute for two or three years is capital-inefficient, especially with dilution pressure tighter than it was a few years ago. Meanwhile your CEO is spending real time each week on marketing and commercial decisions they're not equipped to make. That gap between 'we need commercial leadership' and 'we can afford a full-time executive' is where most biotech companies stall.
Agency relationships lack strategic accountability
Most biotech companies fill the leadership gap with agency relationships – a PR firm, a medical communications agency, a digital shop. Agencies execute tactics. Nobody owns the commercial strategy that connects those tactics to business outcomes. You end up with disconnected workstreams, no integrated measurement, and a CEO still making every strategic marketing call.
Commercial launch readiness takes years to build, not months
Companies that launch well build commercial infrastructure 18-24 months before approval. Market access strategy, KOL development, medical affairs content, payer engagement – none of it compresses into a six-month pre-launch sprint. Without senior commercial leadership guiding these workstreams early, you're building on a timeline that guarantees a weaker launch.
How We Help
Our initial assessment evaluates commercial readiness across five dimensions: market positioning, go-to-market infrastructure, team capabilities, agency relationships, and competitive preparedness. Most biotech companies score well on the science and poorly on commercial readiness – not because the team is weak, but because nobody with commercial experience has been guiding those decisions.
A fractional CXO embeds in your leadership team 2-3 days per week, owning commercial strategy with the same accountability as a full-time executive. The difference is cost efficiency and flexibility. Your fractional CXO builds the commercial plan, hires and manages agencies, develops the marketing team, and represents commercial interests in board and investor meetings, bringing pattern recognition from multiple biotech commercializations that a first-time CMO hire can't offer.
Execution scales to your pipeline stage. Pre-clinical companies need brand strategy and investor positioning. Clinical-stage companies need KOL development, medical affairs content, and market access groundwork. Pre-launch companies need full commercial readiness programs. Your fractional CXO shifts focus as your pipeline matures rather than running one fixed playbook.
Measurement tracks commercial readiness milestones tied to your pipeline timeline – brand positioning completion, agency selection, market access strategy development – reported to leadership and the board each quarter. The goal is that when you're ready for a full-time commercial leader, the strategy, infrastructure, and team are already built.
What we deliver
- Commercial strategy – integrated plan connecting brand, market access, medical affairs, and launch
- Team development – hiring plans, agency selection, and capability building for your stage
- Board-ready reporting – commercial readiness dashboards and milestone tracking
- Transition planning – building toward a full-time hire with strategy and infrastructure in place
The best time to hire a biotech CMO is 18 months before launch. The best time to start building commercial strategy is now. A fractional CXO bridges that gap – giving you senior leadership on a timeline and budget that matches your pipeline, not your org chart.
Our Methodology
Our fractional CXO engagement for biotech follows a stage-gated approach aligned to your pipeline. Phase one, the first 30 days, is a comprehensive commercial audit – positioning, competitive landscape, KOL relationships, market access readiness, and team capabilities. This produces a prioritized commercial roadmap mapped directly to your clinical development timeline.
Phase two builds the foundational commercial infrastructure. Depending on stage, that means developing brand architecture, selecting and onboarding agencies, building medical affairs content programs, or initiating payer engagement strategy. Your fractional CXO drives these workstreams with the same authority as a full-time executive.
Phase three is ongoing execution and scaling. As you progress through clinical milestones, commercial activity scales with it. The fractional model lets you increase engagement intensity approaching launch without committing to full-time executive compensation during earlier stages when part-time leadership is enough.
How We Work
Fractional CXO engagements for biotech typically start at 2-3 days per week and run 12-24 months, scaling intensity as your pipeline progresses. The first 30 days are an immersive commercial audit where your fractional CXO learns the science, meets the team, evaluates existing commercial activity, and builds the strategic roadmap.
Months 2-6 focus on foundational infrastructure – brand strategy, agency selection, initial content programs, and market access groundwork. Your fractional CXO attends leadership meetings, board sessions, and investor conversations as a core member of your executive team.
Months 6-24 are execution against the commercial roadmap with quarterly milestone reviews. Engagement intensity scales with pipeline progress, moving from 2 days per week during early clinical to 4-5 days approaching launch preparation. The goal is to hand off to a full-time commercial leader who inherits a functioning strategy and infrastructure, not a blank slate.
Weekly executive check-ins and monthly board reporting keep all stakeholders aligned on commercial progress throughout.
- Commercial readiness – strategy and infrastructure built on your pipeline timeline
- Capital efficiency – senior leadership without full-time executive compensation during early stages
- Launch preparedness – market access, KOL, and medical affairs programs built years before approval
If your biotech & pharma company needs fractional cxo leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a fractional CXO cost for biotech companies?
Fractional CXO engagements typically run $20K-$50K per month depending on time commitment and scope. At 2-3 days per week that's roughly 40-60% less than a full-time CMO's total compensation, which now regularly clears $400K-$550K base plus equity in this market. The fractional model also removes the risk of a bad executive hire, which in biotech can cost 12-18 months of lost commercial development time.
How long does a fractional CXO engagement typically last?
Most engagements run 12-24 months, aligned to clinical development timelines. The goal is building commercial strategy and infrastructure to the point where a full-time commercial leader makes sense, typically approaching Phase III or pre-launch. Some companies extend the fractional engagement through launch when the model is working and a full-time hire isn't yet the right fit.
How does a fractional CXO integrate with our existing leadership team?
Your fractional CXO operates as a member of the executive team – attending leadership meetings, board sessions, and investor conversations. They manage agency relationships, develop commercial hiring plans, and own the commercial strategy with full accountability. The only difference from a full-time executive is time allocation, not authority.
What makes Winston Francois different from hiring a traditional interim CMO?
Interim CMOs are typically hired to fill a gap while a company searches for a permanent replacement. A fractional CXO builds the commercial strategy from scratch, develops the infrastructure, and defines the role for the eventual full-time hire. We also bring pattern recognition from multiple biotech commercializations, which means faster, more informed decisions than a single-company executive can provide.
How do you measure the impact of a fractional CXO?
We set quarterly commercial readiness milestones tied to your pipeline timeline: brand strategy completion, agency ecosystem development, KOL program establishment, market access milestones, and team capability building. Board-ready dashboards track progress against these milestones. The ultimate measure is whether your company is commercially ready when the science delivers.
What stage of biotech company benefits most from a fractional CXO?
Series A through pre-launch companies benefit most. Series A companies need commercial strategy to support fundraising narratives. Series B companies need to start building commercial infrastructure. Pre-launch companies need to accelerate commercial readiness fast. If you're already launched and generating revenue, you likely need a full-time commercial leader, not a fractional one – the first step either way is a commercial readiness assessment.
